Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading Institutional Investors

March 11, 2018

Responsive image

NEW HAVEN, Conn., March 12, 2018 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (“Biohaven” or the “Company”) announced today a restructuring of its global license agreement with Bristol-Myers Squibb Company (NYSE: BMY) (“BMS”) for Biohaven’s small molecule…

Category: Precious Metals